CN1351600A - 制备[S－(R*,S*)]－β－[[[1－[1－氧代－3－(4－(哌啶基)丙基]－3－哌啶基]羰基]氨基]－3－吡啶丙酸及其衍生物的方法 - Google Patents

制备[S－(R*,S*)]－β－[[[1－[1－氧代－3－(4－(哌啶基)丙基]－3－哌啶基]羰基]氨基]－3－吡啶丙酸及其衍生物的方法 Download PDF

Info

Publication number
CN1351600A
CN1351600A CN00807617A CN00807617A CN1351600A CN 1351600 A CN1351600 A CN 1351600A CN 00807617 A CN00807617 A CN 00807617A CN 00807617 A CN00807617 A CN 00807617A CN 1351600 A CN1351600 A CN 1351600A
Authority
CN
China
Prior art keywords
formula
compound
salt
hydrogen
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00807617A
Other languages
English (en)
Chinese (zh)
Inventor
J·H·科亨
M·朱斯图斯
C·A·马亚诺夫
A·罗斯勒
F·H·施罗德
K·L·索尔吉
小F·J·维拉尼
C·维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of CN1351600A publication Critical patent/CN1351600A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN00807617A 1999-03-22 2000-03-21 制备[S－(R*,S*)]－β－[[[1－[1－氧代－3－(4－(哌啶基)丙基]－3－哌啶基]羰基]氨基]－3－吡啶丙酸及其衍生物的方法 Pending CN1351600A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12567199P 1999-03-22 1999-03-22
US60/125,671 1999-03-22

Publications (1)

Publication Number Publication Date
CN1351600A true CN1351600A (zh) 2002-05-29

Family

ID=22420863

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00807617A Pending CN1351600A (zh) 1999-03-22 2000-03-21 制备[S－(R*,S*)]－β－[[[1－[1－氧代－3－(4－(哌啶基)丙基]－3－哌啶基]羰基]氨基]－3－吡啶丙酸及其衍生物的方法

Country Status (22)

Country Link
US (2) US6515130B1 (cg-RX-API-DMAC7.html)
EP (1) EP1165543B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002540108A (cg-RX-API-DMAC7.html)
KR (1) KR20020019895A (cg-RX-API-DMAC7.html)
CN (1) CN1351600A (cg-RX-API-DMAC7.html)
AT (1) ATE242235T1 (cg-RX-API-DMAC7.html)
AU (1) AU775413B2 (cg-RX-API-DMAC7.html)
BR (1) BR0010652A (cg-RX-API-DMAC7.html)
CA (1) CA2368024A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20013431A3 (cg-RX-API-DMAC7.html)
DE (1) DE60003169T2 (cg-RX-API-DMAC7.html)
DK (1) DK1165543T3 (cg-RX-API-DMAC7.html)
ES (1) ES2199805T3 (cg-RX-API-DMAC7.html)
HK (1) HK1046272A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20010767A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0201262A3 (cg-RX-API-DMAC7.html)
MX (1) MXPA01009615A (cg-RX-API-DMAC7.html)
PT (1) PT1165543E (cg-RX-API-DMAC7.html)
SK (1) SK13562001A3 (cg-RX-API-DMAC7.html)
UA (1) UA67832C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000056730A1 (cg-RX-API-DMAC7.html)
YU (1) YU74601A (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002540101A (ja) 1999-03-22 2002-11-26 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド プロピオン酸３−アミノ−３−アリールの合成
SI1430057T1 (sl) * 2001-09-21 2006-02-28 Sanofi Aventis Substituirani 2-piridinil-6,7,8,9-tetrahidropirimido -(1,2-a)pirimidin-4-onski in 7-piridinil-2,3-dihidroimidazo -(1,2-a)pirimidin-5(1H)onski derivati
DK2744802T3 (en) 2011-08-17 2017-04-03 Piramal Imaging Sa CONNECTIONS FOR BINDING TO THE TROMBOCYTE SPECIFIC GLYCOPROTEIN IIB / IIIA AND ITS APPLICATION FOR IMAGE DIAGNOSIS OF TROMBER
WO2014124943A1 (en) 2013-02-12 2014-08-21 Bayer Pharma Aktiengesellschaft Metal chelate compounds for binding to the platelet specific glycoprotein iib/iiia
ES2777200T3 (es) 2013-02-20 2020-08-04 Reuter Chemische Apparatenbau Ek Procedimiento para la preparación de 3-aminopiperidina enriquecida enantioméricamente
WO2014173855A1 (en) 2013-04-22 2014-10-30 Reuter Chemische Apparatebau Kg Process for preparing enantiomerically enriched 3-hydroxymethylpiperidine
KR102548998B1 (ko) 2020-03-31 2023-06-29 재단법인 아산사회복지재단 혈전영상을 위한 방사성의약품 및 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58243B1 (en) 1983-12-07 1993-08-11 Lonza Ag A process for the preparation of optically-active 3-amino carboxylic acids
US5254573A (en) 1991-10-15 1993-10-19 Monsanto Company Substituted heterocyclic derivatives useful as platelet aggregation inhibitors
DK0669912T3 (da) * 1993-09-22 2002-03-04 Fujisawa Pharmaceutical Co N-(3-Piperidinylcarbonyl)-beta-alaninderivater som PAF-antagonister
US5770575A (en) * 1994-03-16 1998-06-23 Ortho Pharmaceutical Corporation Nipecotic acid derivatives as antithrombotic compounds
EP0888302A1 (en) * 1996-03-13 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. N- (r)-1- 3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine as fibrinogen receptor antagonist
RU2194038C2 (ru) * 1996-05-01 2002-12-10 Орто-Макнейл Фармасьютикал, Инк. Карбоксамидные производные пирролидина или пиперидина, фармацевтическая композиция на их основе и способ ингибирования агрегации тромбоцитов
ATE209179T1 (de) 1996-07-12 2001-12-15 Searle & Co Asymmetrische synthese von chiralen beta- aminosäuren
US6066651A (en) * 1997-10-29 2000-05-23 Ortho-Mcneil Pharmaceutical, Inc. Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders

Also Published As

Publication number Publication date
WO2000056730A1 (en) 2000-09-28
MXPA01009615A (es) 2003-07-21
DE60003169T2 (de) 2005-10-27
HUP0201262A3 (en) 2003-12-29
ES2199805T3 (es) 2004-03-01
HRP20010767A2 (en) 2002-12-31
AU3766100A (en) 2000-10-09
CZ20013431A3 (cs) 2003-04-16
JP2002540108A (ja) 2002-11-26
EP1165543A1 (en) 2002-01-02
HUP0201262A2 (en) 2002-08-28
KR20020019895A (ko) 2002-03-13
YU74601A (sh) 2004-05-12
UA67832C2 (uk) 2004-07-15
US20020137937A1 (en) 2002-09-26
AU775413B2 (en) 2004-07-29
EP1165543B1 (en) 2003-06-04
SK13562001A3 (sk) 2002-08-06
ATE242235T1 (de) 2003-06-15
US6515130B1 (en) 2003-02-04
DK1165543T3 (da) 2003-09-29
HK1046272A1 (zh) 2003-01-03
CA2368024A1 (en) 2000-09-28
DE60003169D1 (de) 2003-07-10
PT1165543E (pt) 2003-10-31
BR0010652A (pt) 2002-07-16
HU0201262D0 (cg-RX-API-DMAC7.html) 2002-05-29

Similar Documents

Publication Publication Date Title
CN100418964C (zh) (s,s)-顺式-2-二苯甲基-3-苄基氨基奎宁环的制备方法
CN1867564A (zh) 氨基巴豆基化合物的制备方法
CN1135209A (zh) 新的氨基甲酸苯基烷基氨基醇酯及其制备方法
JP2006501236A (ja) ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有３，６−二置換アザビシクロ（３．１．０）ヘキサン誘導体
CN1377268A (zh) 细胞粘合抑制剂
BG107635A (bg) Метод за получаване на n-арил-антранилови киселини и техни производни
CN1930127A (zh) 用于合成cxcr4拮抗剂的方法
CN103080088B (zh) 用于合成药物的中间体化合物的制备方法
CN1351600A (zh) 制备[S－(R*,S*)]－β－[[[1－[1－氧代－3－(4－(哌啶基)丙基]－3－哌啶基]羰基]氨基]－3－吡啶丙酸及其衍生物的方法
EA009277B1 (ru) Способ получения высокочистого периндоприла и промежуточных веществ, пригодных для синтеза
CN1301963C (zh) 制备n－(4－氟苯基)－n－(2－羧基－4－氯苯基)甘氨酸的方法
TWI386395B (zh) 哌啶衍生物的立體有擇合成
CN1255402C (zh) 用于制备喹诺酮羧酸衍生物的中间体
CN1199969C (zh) 新方法
CN115594613B (zh) 依度沙班中间体及其制备方法
AU2014220865A1 (en) Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide
CN1377350A (zh) 制备二氮杂萘－3－羧酸衍生物的方法
CN1046716C (zh) 供合成用的新中间体和用于制造氨基哌嗪衍生物的方法
KR101469015B1 (ko) 몬테루카스트의 제조방법 및 이에 사용되는 중간체
US20080139823A1 (en) Process for the Purification of Perindopril
KR102184129B1 (ko) 의약품 합성용 중간체 화합물의 제조 방법
CN112341354B (zh) 一种pms的合成方法
CN1168669A (zh) 制备雷尼替丁的新方法
CN102531987B (zh) (s)‑3‑氨基吡咯烷二盐酸盐的合成方法
JPH08253497A (ja) ペプチド型化合物

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1046272

Country of ref document: HK